Amplia Therapeutics Completes Early Recruitment for Pancreatic Cancer Trial

MT Newswires Live

Jan 31, 2025

Amplia Therapeutics (ASX:ATX) enrolled 53 patients with pancreatic cancer for its ACCENT Phase 2a clinical trial, completing recruitment two months ahead of schedule, according to a Friday Australian bourse filing.

The two-stage trial explores the use of Amplia's focal adhesion kinase inhibitor narmafotinib in combination with chemotherapy in first-line patients with advanced pancreatic cancer.

The first stage of the trial identified a safe and tolerated daily oral dose of narmafotinib. It was completed in November 2023.

The second stage will explore the efficacy of the safe dose of narmafotinib. Preliminary safety, tolerability, and efficacy data were earlier reported for the initial 26 patients.

It reported a 38.5% objective response rate from the second stage, exceeding historical benchmarks. It also reported a median trial duration of 197 days for the first 26 patient groups, indicating a 68% improvement over historical data of 117 days.

The total number of patients remaining in the study is 35.

The firm's shares rose over 7% on market close on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2507294936"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507294936\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2507294936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-31 15:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507294936","market":"sh","top_or_hot":-1,"title":"Amplia Therapeutics Completes Early Recruitment for Pancreatic Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:ATX) enrolled 53 patients with pancreatic cancer for its ACCENT Phase 2a clinical trial, completing recruitment two months ahead of schedule, according to a Friday Australian bourse filing.</p><p>The two-stage trial explores the use of Amplia's focal adhesion kinase inhibitor narmafotinib in combination with chemotherapy in first-line patients with advanced pancreatic cancer.</p><p>The first stage of the trial identified a safe and tolerated daily oral dose of narmafotinib. It was completed in November 2023.</p><p>The second stage will explore the efficacy of the safe dose of narmafotinib. Preliminary safety, tolerability, and efficacy data were earlier reported for the initial 26 patients.</p><p>It reported a 38.5% objective response rate from the second stage, exceeding historical benchmarks. It also reported a median trial duration of 197 days for the first 26 patient groups, indicating a 68% improvement over historical data of 117 days.</p><p>The total number of patients remaining in the study is 35.</p><p>The firm's shares rose over 7% on market close on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Completes Early Recruitment for Pancreatic Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Completes Early Recruitment for Pancreatic Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-31 15:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:ATX) enrolled 53 patients with pancreatic cancer for its ACCENT Phase 2a clinical trial, completing recruitment two months ahead of schedule, according to a Friday Australian bourse filing.</p><p>The two-stage trial explores the use of Amplia's focal adhesion kinase inhibitor narmafotinib in combination with chemotherapy in first-line patients with advanced pancreatic cancer.</p><p>The first stage of the trial identified a safe and tolerated daily oral dose of narmafotinib. It was completed in November 2023.</p><p>The second stage will explore the efficacy of the safe dose of narmafotinib. Preliminary safety, tolerability, and efficacy data were earlier reported for the initial 26 patients.</p><p>It reported a 38.5% objective response rate from the second stage, exceeding historical benchmarks. It also reported a median trial duration of 197 days for the first 26 patient groups, indicating a 68% improvement over historical data of 117 days.</p><p>The total number of patients remaining in the study is 35.</p><p>The firm's shares rose over 7% on market close on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507294936","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507294936","pubTimestamp":1738306971,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  enrolled 53 patients with pancreatic cancer for its ACCENT Phase 2a clinical trial, completing recruitment two months ahead of schedule, according to a Friday Australian bourse filing.The two-stage trial explores the use of Amplia's focal adhesion kinase inhibitor narmafotinib in combination with chemotherapy in first-line patients with advanced pancreatic cancer.The first stage of the trial identified a safe and tolerated daily oral dose of narmafotinib. It was completed in November 2023.The second stage will explore the efficacy of the safe dose of narmafotinib. Preliminary safety, tolerability, and efficacy data were earlier reported for the initial 26 patients.It reported a 38.5% objective response rate from the second stage, exceeding historical benchmarks. It also reported a median trial duration of 197 days for the first 26 patient groups, indicating a 68% improvement over historical data of 117 days.The total number of patients remaining in the study is 35.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATX.AU":"AMPLIA THERAPEUTICS LTD","BK7067":"生物科技","LENZ":"Therapeutics"},"translate_title":"Amplia Therapeutics完成胰腺癌试验的早期招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ATX.AU":0.9},"content_text":"Amplia Therapeutics (ASX:ATX) enrolled 53 patients with pancreatic cancer for its ACCENT Phase 2a clinical trial, completing recruitment two months ahead of schedule, according to a Friday Australian bourse filing.The two-stage trial explores the use of Amplia's focal adhesion kinase inhibitor narmafotinib in combination with chemotherapy in first-line patients with advanced pancreatic cancer.The first stage of the trial identified a safe and tolerated daily oral dose of narmafotinib. It was completed in November 2023.The second stage will explore the efficacy of the safe dose of narmafotinib. Preliminary safety, tolerability, and efficacy data were earlier reported for the initial 26 patients.It reported a 38.5% objective response rate from the second stage, exceeding historical benchmarks. It also reported a median trial duration of 197 days for the first 26 patient groups, indicating a 68% improvement over historical data of 117 days.The total number of patients remaining in the study is 35.The firm's shares rose over 7% on market close on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}